Sundaram-Clayton (SUNCLAY) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
21 Aug, 2026Executive summary
EBITDA grew 16% year-over-year to Rs. 70.6 Cr in Q1 FY 2025-26 from Rs. 61.1 Cr in Q1 2024-25.
Standalone revenue for Q1 FY 2025-26 was Rs. 444.1 Cr, down from Rs. 553.6 Cr in Q1 2024-25, reflecting the sale of the Hosur business in Q4 FY 2024-25.
Segment performance
India operations ramped up smoothly at the new Thervoy Kandigai Plant, with consolidation of three plants into two nearing completion.
US operations achieved record quarterly sales of Rs. 79.7 Cr in Q1 FY 2025-26, up 32% year-over-year, driven by the operationalization of a new 4,400 Ton machine.
Outlook and guidance
North American market remains volatile with ongoing softness, but is viewed as a long-term strategic growth opportunity.
Operational efficiencies expected from plant consolidation in India.
Latest events from Sundaram-Clayton
- Consolidated losses widened due to overseas subsidiaries despite stable standalone performance.SUNCLAY
Q1 24/25 - Standalone profit improved, but consolidated loss persisted due to overseas operations and high debt.SUNCLAYQ2 24/25
- Standalone profit and consolidated loss reported for Q3 FY25; leverage remains elevated.SUNCLAYQ3 24/25
- EBITDA and PAT improved in FY25, driven by new facility launch and operational consolidation.SUNCLAYQ4 24/25
- EBITDA rose 9% year-over-year in Q2 FY2025-26, with strong operational and ESG performance.SUNCLAYQ2 25/26
- EBITDA margin improved to 19.7% in Q3 FY26, with higher standalone profit and operational gains.SUNCLAYQ3 25/26
- EBITDA margins rose and operational resilience strengthened, despite lower revenue from divestment.SUNCLAYQ4 25/26
- Standalone revenue up 19% YoY, but margins pressured by rising input costs.SUNCLAYQ1 26/27